Stock CBPO CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

China Biologic Products Holdings, Inc.

Equities

CBPO

KYG215151047

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about China Biologic Products Holdings, Inc.

China Biologic Products Holdings, Inc.(NasdaqGS:CBPO) dropped from S&P Global BMI Index CI
China Biologic Products Holdings, Inc.(NasdaqGM:CBPO) dropped from FTSE All-World Index CI
China Biologic Products Holdings, Inc.(NasdaqGS:CBPO) dropped from NASDAQ Biotechnology Index CI
China Biologic Products Holdings, Inc.(NasdaqGM:) dropped from NASDAQ Composite Index CI
Centurium Capital Management Ltd., CITIC Capital Partners Management Ltd., Parfield International Ltd., V-Sciences Investments Pte Ltd, Hillhouse Capital Management, Ltd. and Joseph Chow, Chairman and Chief Executive Officer of China Biologic Products Holdings, Inc. completed the acquisition of remaining 31.16% stake in China Biologic Products Holdings, Inc.. CI
China Biologic Products Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
China Biologic Products : Q4 Profit, Revenue Rise from Year Ago MT
China Biologic Products Holdings, Inc. Announces Resignation of Yue’e Zhang from the Board of Directors CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO completed the acquisition of 9.72% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited. CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO completed the acquisition of 2% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited. CI
CITIC Capital Holdings Limited completed the acquisition of 2.4% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited. CI
Transcript : China Biologic Products Holdings, Inc., Q3 2020 Earnings Call, Nov 25, 2020
China Biologic Products Holdings, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
China Biologic Products : Q3 Adj. EPS Slips From Year-Ago Levels But Sales Climb Nearly 2% MT
China Biologic Products : to Merge With CBPO Group in Going-Private Deal; Shares Gain Pre-Bell MT
Centurium Capital Management Ltd., CITIC Capital Partners Management Ltd., Parfield International Ltd., V-Sciences Investments Pte Ltd, Hillhouse Capital Management, Ltd. and Joseph Chow entered into a definitive Agreement and Plan of Merger to acquire remaining 31.16% stake in China Biologic Products Holdings, Inc. for $1.6 billion. CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO entered into a share purchase agreement to acquire 9.72% stake in China Biologic Products Holdings, Inc. for approximately $450 million. CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO entered into a share purchase agreement to acquire 2% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited for $93 million. CI
CITIC Capital Holdings Limited entered into an agreement to acquire 2.4% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited for approximately $110 million. CI
Transcript : China Biologic Products Holdings, Inc., Q2 2020 Earnings Call, Aug 18, 2020
China Biologic Products Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
Transcript : China Biologic Products Holdings, Inc., Q1 2020 Earnings Call, May 21, 2020
China Biologic Products Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction CI
Hillhouse Capital Provides Information to Shareholders of China Biologic CI

Chart China Biologic Products Holdings, Inc.

Chart China Biologic Products Holdings, Inc.
More charts

Company Profile

China Biologic Products Holdings Inc is a China-based company. The Company operates as a biopharmaceutical company. The Company research, develop, and produces human plasma-based pharmaceutical and coagulation factor products in the form of tablets, injections, capsules, and syrups. Company also distributes pharmaceutical products. It serves clients in China.
Sector
Biotechnology & Medical Research
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CBPO Stock
  4. News China Biologic Products Holdings, Inc.
  5. China Biologic Products : Q4 Profit, Revenue Rise from Year Ago